Zacks: Atossa Genetics Inc (ATOS) Given $9.00 Consensus Price Target by Brokerages

Shares of Atossa Genetics Inc (NASDAQ:ATOS) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $9.00 for the company, according to Zacks. Zacks has also given Atossa Genetics an industry rank of 145 out of 256 based on the ratings given to related companies.

Several equities research analysts have issued reports on the stock. Maxim Group reissued a “buy” rating and issued a $9.00 price target on shares of Atossa Genetics in a report on Tuesday, March 26th. ValuEngine lowered shares of Atossa Genetics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.

Atossa Genetics stock traded up $0.01 on Wednesday, hitting $2.55. The company’s stock had a trading volume of 83,500 shares, compared to its average volume of 2,392,217. The firm has a market capitalization of $23.18 million, a PE ratio of -0.46 and a beta of 3.68. Atossa Genetics has a one year low of $0.80 and a one year high of $7.39.

A number of institutional investors have recently made changes to their positions in the business. Ahrens Investment Partners LLC bought a new stake in Atossa Genetics in the 1st quarter valued at $35,000. Virtu Financial LLC increased its holdings in Atossa Genetics by 405.1% in the 4th quarter. Virtu Financial LLC now owns 69,903 shares of the company’s stock valued at $71,000 after buying an additional 56,064 shares during the period. Finally, Barclays PLC bought a new stake in Atossa Genetics in the 4th quarter valued at $33,000. 9.31% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Read More: What moving averages are used to define a golden cross?

Get a free copy of the Zacks research report on Atossa Genetics (ATOS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.